Key terms
About ESPR
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ESPR news
Apr 07
4:44pm ET
Esperion presents new data from CLEAR Outcomes at ACC.24
Apr 03
8:22am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 28
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Mar 27
10:47am ET
Biotech Alert: Searches spiking for these stocks today
Mar 26
6:15am ET
Esperion’s Market Expansion and Positive Sales Outlook Merit a Buy Rating
Mar 25
1:05pm ET
Buy Rating Affirmed for Esperion on Growth Potential Post-FDA Approval
Mar 25
9:41am ET
Unusually active option classes on open March 25th
Mar 25
9:25am ET
Expanding Market Potential: Buy Rating Affirmed for Esperion Following FDA Approval for NEXLETOL and NEXLIZET Label Expansions
Mar 25
8:55am ET
Northland Securities Sticks to Their Hold Rating for Esperion (ESPR)
Mar 25
6:46am ET
Expanding Market Potential Justifies Buy Rating for Esperion Following FDA Approval
Mar 25
5:30am ET
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Masimo (MASI)
Mar 22
3:12pm ET
Esperion: FDA approves broad new labels for NEXLETOL and NEXLIZET
Mar 22
11:08am ET
Esperion reports CHMP issues positive opinions on Nilemdo and Nustendi
Mar 22
7:58am ET
Jefferies sees Esperion takeout potential rising after near-term catalysts
Feb 28
6:32am ET
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
Feb 28
6:16am ET
Esperion price target lowered to $16 from $22 at H.C. Wainwright
Feb 28
5:53am ET
Esperion’s Market Position and Outlook: A Hold Rating with a Revised Price Objective
Feb 27
2:25pm ET
Buy Rating Affirmed for Esperion on Potential Market Expansion and Financial Fortification
Feb 27
1:50pm ET
Analysts’ Top Healthcare Picks: Esperion (ESPR), Nuvalent (NUVL)
Feb 27
6:04am ET
Esperion sees 2024 operating expenses $225M-$245M
Feb 27
6:03am ET
Esperion reports Q4 EPS (50c), consensus (48c)
Feb 16
8:45am ET
Largest borrow rate increases among liquid names
Jan 23
3:01am ET
Esperion Announces and Prices New Offering Same Day
Jan 23
3:01am ET
Esperion Announces Major Public Stock Offering Deal
Jan 18
9:31pm ET
Esperion 56.7M share Spot Secondary priced at $1.50
Jan 18
4:01pm ET
Esperion announce common stock offering, no amount given
No recent news articles are available for ESPR
No recent press releases are available for ESPR
ESPR Financials
Key terms
Ad Feedback
ESPR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ESPR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
